Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

Literature DB >> 1820493

Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

R Lewensohn¹, J O Fernberg, H Ehrsson, G Merlini.

Abstract

Peptichemio (PTC) is a mixture of six synthetic oligopeptides, each containing the alkylating agent m-di(2-chloroethyl)amino-phenylalanine. Freshly obtained myeloma cell infiltrated human bone marrow specimens were in parallel exposed to melphalan and PTC. The cytotoxic effect of the drugs on the myeloma cells of each specimen was measured by the differential staining culture method (DISC). PTC displayed higher cytotoxicity to the myeloma cells as compared to melphalan in all 12 cases analysed. The increase of the cytotoxic effect of PTC compared to melphalan varied between different cases. In melphalan resistant cases the cytotoxic effect of PTC as compared to melphalan was clearly significant (P = 0.001).

Entities: Chemical Disease Species

Mesh：

Substances：
Peptichemio
Melphalan

Year: 1991 PMID： 1820493 DOI： 10.1007/BF02987196

Source DB: PubMed Journal: Med Oncol Tumor Pharmacother ISSN： 0736-0118

14 in total

1. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

Authors: L M Weisenthal; P L Dill; J Z Finklestein; T E Duarte; J A Baker; E M Moran
Journal: Cancer Treat Rep Date: 1986-11

2. Separation of leukocytes from blood and bone marrow. Introduction.

Authors: A Böyum
Journal: Scand J Clin Lab Invest Suppl Date: 1968

3. Peptichemio, teniposide and high-dose dexamethasone: a new active combination for relapsing and refractory multiple myeloma. A pilot study.

Authors: A Zaniboni; E Simoncini; P Marpicati; E Montini; G Rossi; G Marini
Journal: Anticancer Res Date: 1988 Jan-Feb Impact factor: 2.480

4. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.

Authors: R Lewensohn; H Ehrsson; J Hansson; U Ringborg
Journal: Anticancer Res Date: 1991 Jan-Feb Impact factor: 2.480

2. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors: R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal: Br J Cancer Date: 1998-08 Impact factor: 7.640

2 in total

Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

1. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

2. Separation of leukocytes from blood and bone marrow. Introduction.

3. Peptichemio, teniposide and high-dose dexamethasone: a new active combination for relapsing and refractory multiple myeloma. A pilot study.

4. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.

5. A phase II study of peptichemio in advanced breast cancer.

6. Peptichemio in pretreated patients with plasmacell neoplasms.

7. Peptichemio induction therapy in myelomatosis.

8. Peptichemio in pretreated patients with ovarian cancer.

9. Interferon exerts a cytotoxic effect on primary human myeloma cells.

10. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.

1. Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.

2. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.